Agile Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results
March 12, 2018 16:15 ET
|
Agile Therapeutics, Inc.
PRINCETON, N.J., March 12, 2018 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq:AGRX), a women's healthcare company, today reported financial results for the three months and year ended...
Global Intra-Uterine Contraceptive Device (IUDs), a Safer Way to Birth Control Measure with Reversible Contraception is Expected to Reach USD 5.27 Billion by 2023
January 31, 2018 06:49 ET
|
Energias Market Research
NEW YORK, Jan. 31, 2018 (GLOBE NEWSWIRE) -- The global intra-uterine contraceptive device market is expected to grow steadily from USD 3.80 billion in 2016 to USD 5.27 billion in 2023, at a CAGR of...
Agile Therapeutics to Host First Analyst Day on October 10, 2017
October 02, 2017 07:30 ET
|
Agile Therapeutics, Inc.
PRINCETON, N.J., Oct. 02, 2017 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc., (NASDAQ:AGRX), a women's healthcare company, today announced that the Company will host its first Analyst Day on Tuesday,...
Agile Therapeutics Announces Pricing of Its Public Offering of Common Stock
August 03, 2017 08:23 ET
|
Agile Therapeutics, Inc.
PRINCETON, N.J., Aug. 03, 2017 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq:AGRX), a forward-thinking women’s healthcare company, today announced the pricing of its underwritten public...
Agile Therapeutics Announces Proposed Offering of Common Stock
August 02, 2017 16:05 ET
|
Agile Therapeutics, Inc.
PRINCETON, N.J., Aug. 02, 2017 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq:AGRX), a forward-thinking women’s healthcare company, today announced that it intends to offer and sell shares of...
Agile Therapeutics Reports Second Quarter 2017 Financial Results
July 28, 2017 07:30 ET
|
Agile Therapeutics, Inc.
Cash Expected to Fund Operations into Q2 2018 FDA Assigns Prescription Drug User Fee Act (PDUFA) Goal Date of December 26, 2017 PRINCETON, N.J., July 28, 2017 (GLOBE NEWSWIRE) -- Agile...
Agile Therapeutics Announces FDA Acceptance of the NDA Resubmission of Twirla®
July 27, 2017 16:11 ET
|
Agile Therapeutics, Inc.
PRINCETON, N.J., July 27, 2017 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq:AGRX), a forward-thinking women’s healthcare company, today announced that the U.S. Food and Drug Administration...
Agile Therapeutics Resubmits New Drug Application (NDA) for its Transdermal Contraceptive Patch, Twirla®
June 27, 2017 08:00 ET
|
Agile Therapeutics, Inc.
PRINCETON, N.J., June 27, 2017 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc., (NASDAQ:AGRX), a women’s healthcare company, today announced it has resubmitted to the U.S. Food and Drug Administration...
Agile Therapeutics to Present Additional Phase 3 Data at the 2017 Annual Clinical and Scientific Meeting of the American Congress of Obstetricians and Gynecologists
May 03, 2017 16:15 ET
|
Agile Therapeutics, Inc.
PRINCETON, N.J., May 03, 2017 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc., (NASDAQ:AGRX), a women's healthcare company today announced that data from its Phase 3 SECURE study will be presented at...
Agile Therapeutics Announces Presentation of SECURE Phase 3 Data at the 2017 Congress on Women’s Health
April 27, 2017 07:30 ET
|
Agile Therapeutics, Inc.
PRINCETON, N.J., April 27, 2017 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (NASDAQ:AGRX), a women's healthcare company announced today that a presentation entitled “An Update on Hormonal...